Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chart: Waxman vs. Kennedy: A Side-By-Side Comparison of Drug Safety Bills From The House And Senate

You may also be interested in...



FDA Reform Bill Goes Back To The Future In House With Tighter Safety Rules

The discussion drafts of the FDA reform legislation being circulated by the House Energy and Commerce Committee contain many provisions that were removed during debate in Senate

Phase I Trial Registration Required For Publication, Medical Journals Say

Researchers will soon have to register their Phase I trial protocols, as well as Phase II and III data, in order to get their studies published in medical journals

Can Congress ban DTC?

A ban on direct-to-consumer advertising would survive a legal challenge because FDA would be able to apply it only to specific drugs in cases where the public's health is at risk, according to Rachel Sher, health counsel to Rep. Henry Waxman, D.-Calif. Sher's comments were part of a New England Journal of Medicine perspective piece by Miriam Schuchman, released May 2, that raises arguments about the protection of commercial speech. Two drug safety bills on Capitol Hill include provisions that would require a moratorium on DTC advertising (1"The Pink Sheet" March 26, 2007, p. 5). In the article, former FDA Chief Counsel Daniel Troy argues that "the fact that there's a doctor who intervenes ... would knock out any limit on drug advertising"...

Related Content

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel